DEMİRCİ, N. S. Et Al. 2024. Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study. Medicine (United States) , vol.103, no.9 .

DEMİRCİ, N. S., AZİZY, A., Paksoy, N., Doǧan, I., KARABULUT, S., Karahan, L., ... TAŞTEKİN, D.(2024). Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study. Medicine (United States) , vol.103, no.9.

DEMİRCİ, NEBİ Et Al. "Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study," Medicine (United States) , vol.103, no.9, 2024

DEMİRCİ, NEBİ S. Et Al. "Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study." Medicine (United States) , vol.103, no.9, 2024

DEMİRCİ, N. S. Et Al. (2024) . "Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study." Medicine (United States) , vol.103, no.9.

@article{article, author={NEBİ SERKAN DEMİRCİ Et Al. }, title={Comparison of efficacy and safety of 5-FU or capecitabine combined with cisplatin and docetaxel (mDCF and mDCX) as a first-line chemotherapy regimen in her 2-negative metastatic gastric cancer patients: A retrospective study}, journal={Medicine (United States)}, year=2024}